DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ligelizumab
Ligelizumab
WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Novartis R&D and Investor Update
PDCO Minutes of Meeting 18-21 May 2021
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Investor Presentation
Conference Reportpeer-Reviewed
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
Immunfarmakológia Immunfarmakológia
The Two Tontti Tudiul Lui Hi Ha Unit
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
No. RADICADO FECHA DE RADICACION CODIGO
Rxoutlook® 4Th Quarter 2020
Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Top View
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Hypersensitivity Reactions to Biologics (Part I): Allergy As an Important Differential Diagnosis in Complex Immune-Derived Adverse Events
(INN) for Biological and Biotechnological Substances
Biologics in Asthma Are We Turning the Corner?
OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Novartis Pipeline
Rxoutlook® 3Rd Quarter 2020
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Getting Hives Just Thinking About It! Approach to the Work up and Management of Urticaria
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Ige in the Pathogenesis of SLE: from Pathogenic Role to Therapeutic Target
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Novartis R&D
Atopic Dermatitis 9
+ EAACI CONGRESS 2020 Reviewed
Kronik Ürtiker Tedavisinde Omalizumab Dışı Biyolojikler
Draft PDCO Agenda 18-21 May 2021
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
2020 Medicines in Development for Children
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
A View Into Upcoming Specialty & Traditional Drugs
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
PDCO Minutes of the 28-30 April 2020 Meeting
Approaches to Target Ige Antibodies in Allergic Diseases Bianca Balbino, Eva Conde, Thomas Marichal, Philipp Starkl, Laurent Reber
Investor Presentation July 21, 2020 Disclaimer
PDCO Agenda 22-25 June 2021
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Anti-Ige for the Treatment of Chronic Urticaria
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Hypersensitivity Reactions to Biologics (Part I)